Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

41.75SEK
18 May 2018
Change (% chg)

-- (--)
Prev Close
41.75kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,206
52-wk High
84.25kr
52-wk Low
34.10kr

Latest Key Developments (Source: Significant Developments)

Medivir Q4 sales sharply lower, EBITDA loss at 93 mln SEK
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Medivir ::Q4 ‍NET TURNOVER FOR CONTINUING OPERATIONS TOTALED SEK 4.2 MILLION (9.9 M), SEK 4.2 MILLION (7.1 M) OF WHICH COMPRISED Q4'S ROYALTIES​.Q4 ‍LOSS BEFORE INTEREST, TAX, DEPRECIATION AND AMORTIZATION (EBITDA) TOTALED SEK -92.6 MILLION (-125.8 M)​.Q4 ‍CASH FLOW FROM OPERATING ACTIVITIES AMOUNTED TO SEK -88.9 MILLION (-71.8)​.  Full Article

Medivir completes directed issue of around 155 mln SEK
Friday, 2 Feb 2018 

Feb 2 (Reuters) - Medivir Ab ::MEDIVIR HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY 155 MSEK.MEDIVIR SAYS ‍COMPANY INTENDS TO USE NET PROCEEDS FROM DIRECTED ISSUE TO MORE RAPIDLY ADVANCE DEVELOPMENT OF COMPANY'S CLINICAL PORTFOLIO WHILE SIMULTANEOUSLY CONDUCTING OUT-LICENSING DISCUSSIONS FOR MIV-711, WITH AMBITION OF ENTERING INTO A PARTNER AGREEMENT DURING 2018​.  Full Article

Medivir Intends To Make A Directed Share Issue
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Medivir Ab ::MEDIVIR INTENDS TO MAKE A DIRECTED SHARE ISSUE.MEDIVIR - ‍MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT​.MEDIVIR - INTENDS TO EXECUTE A DIRECTED ISSUE OF CLASS B SHARES TO SWEDISH AND INTERNATIONAL QUALIFIED INSTITUTIONAL INVESTORS.  Full Article

Medivir: successful completion of pre-clinical safety studies with MIV-818
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Medivir ::SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018.  Full Article

Medivir says Janssen to terminate Simeprevir license by June 2018
Sunday, 10 Dec 2017 

Dec 10 (Reuters) - Medivir Ab ::MEDIVIR ANNOUNCES JANSSEN DECISION TO TERMINATE ITS SIMEPREVIR LICENSE EFFECTIVE JUNE 2018.SAYS JANSSEN PHARMACEUTICALS INC. HAS DECIDED TO TERMINATE THE LICENSE THAT IT HOLDS FOR SIMEPREVIR DUE TO JANSSEN'S ASSESSMENT OF MARKET DEMAND.  Full Article

Medivir announces new cancer project
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Medivir Ab :Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform.Says Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.Says aim of the Leukotide project is to develop a better tolerated and more effective agent that can lead to improved treatment outcomes for patients with AML and other hematological cancers.  Full Article

Medivir Q3 EBITDA loss widens
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medivir :Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​.Q3 ‍loss before interest, tax, depreciation and amortisation (EBITDA) totalled SEK -78.3 million (-53.9 m)​.  Full Article

Medivir receives FDA fast track designation for MIV-711 for treatment of OA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Medivir :Medivir receives FDA fast track designation for MIV-711 for the treatment of OA.  Full Article

Medivir reports positive data in remetinostat phase II trial ‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Medivir Ab :Medivir says ‍remetinostat phase ii data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage mf-type ctcl​.phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions.  Full Article

Medivir says positive top line data from 6-month initial phase IIa study of MIV-711
Monday, 25 Sep 2017 

Sept 25 (Reuters) - Medivir ::Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients.  Full Article

BRIEF-Medivir Q1 operating loss narrows

* MEDIVIR Q1 NET TURNOVER TOTALED SEK 4.5 MILLION (17.8 M)OF WHICH SEK 4.5 MILLION (13.7 M) COMPRISED THE FIRST QUARTER’S ROYALTIES